share_log

Needham Maintains Buy on Esperion Therapeutics, Lowers Price Target to $10

Needham Maintains Buy on Esperion Therapeutics, Lowers Price Target to $10

Needham 维持对Esperion Therapeutics的买入,将目标价下调至10
Benzinga ·  2023/05/09 12:27

Needham analyst Serge Belanger maintains Esperion Therapeutics (NASDAQ:ESPR) with a Buy and lowers the price target from $12 to $10.

Needham分析师塞尔吉·贝兰格维持Esperion Therapeutics(纳斯达克股票代码:ESPR)的买入,并将目标股价从12美元下调至10美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发